Brevan Howard Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Brevan Howard Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$551K	Sell	3,472 -23,100	-87%	-$3.12M	﹤0.01%	1397
2026 Q1	$3.39M	Buy	26,572 +13,836	+109%	+$1.73M	0.03%	369
2025 Q4	$1.55M	Buy	+12,736	New	+$1.46M	0.02%	581
2025 Q1	–	Sell	-22,764	Closed	-$2.05M	–	1509
2024 Q4	$2.05M	Sell	22,764 -51,750	-69%	-$5.01M	0.01%	279
2024 Q3	$7.36M	Buy	74,514 +42,025	+129%	+$4.13M	0.05%	89
2024 Q2	$3.01M	Buy	+32,489	New	+$2.91M	0.03%	143

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Brevan Howard Capital Management's XBI Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 87% in Q2 2026, selling an estimated $3.12M and leaving 3,472 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Brevan Howard Capital Management first reported a position in XBI in Q2 2024 and has held it in 6 quarters since. The position peaked at $7.36M in Q3 2024. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Brevan Howard Capital Management held 3,472 shares of State Street SPDR S&P Biotech ETF worth $551K as of Q2 2026.
Brevan Howard Capital Management sold 23,100 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $3.12M.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1397 holding.
Brevan Howard Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's State Street SPDR S&P Biotech ETF position peaked at $7.36M in Q3 2024.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.